Formulation and In-Vitro Evaluation of Polymer-Based Extended-Release Pellet Tablets of Diltiazem
Pharmaceutical sciences- Pharmaceutics
DOI:
https://doi.org/10.22376/ijlpr.2023.13.6.P299-P309Keywords:
Eudragit, Extended-Release Pellet Tablets, Dissolution Profile, Release Kinetics, Drug Layered, Stability StudyAbstract
An important development in cardiovascular health is the creation of a blood pressure-lowering extended-releaseformulation. With this novel method, antihypertensive medications are released gradually and continuously, ensuring ideal bloodpressure levels all day long. Reducing the frequency of medicine administration improves ease for patients and adherence, whichhas a positive impact on long-term results. The regulated distribution technique used in this formulation not only increasesefficacy but also reduces the possibility of adverse effects, improving patient comfort and overall quality of life. The extendedrelease formulation has the potential to revolutionise the treatment of hypertension by providing people with high bloodpressure with a more effective and secure option. The main objective is to formulate an Extended-release formulation to lowerBP, which improves patient compliance, reduces the dose frequency, and minimizes the fluctuations seen by immediate-releasetablets, which require multiple dose administration throughout the day. Diltiazem (DTZ) of Extended-release pellet tablets wasformed by using Wurster Coater Granulator to load and coat the pellets with the drug using different polymers, and the Preformulation study was carried out. To check the compatibility of DTZ with other polymers, a DSC and FTIR study was carriedout to make pure and more stable formulations. The pellet tablet products' dissolution profile and physicochemical parametersare compared. DTZ of extended-release pellets in-vitro dissolution study was done using pH 4.5/ 6.8 phosphate buffer usingUSP-2 type method for 2, 3, 4, 6, 8, 12, 18, 24, and 30 hrs. For the drug release profile, significant differences were checked fordifferent formulations. The highest release rate of drug retarding was shown by those with higher polymer content. DSC andFTIR carried out the characterization of DTZ to check the compatibility of the drug with polymers or not. The stability studywas carried out for different months to develop a stable formulation. It was concluded that DTZ of Extended-release pellettablets helps treat hypertension by releasing the drug throughout the day for 30 hours. It helps in lowering BP and preventsvarious cardiovascular complications.
References
Kumar S, Aggarwal G, Kumar A. Extended-release pellet formulations: an overview. Int J Drug Dev Res. 2015;7(4):57-64.
Mehta P, Pawar A. Extended-release pellet technology: an overview. Int J Appl Biol Pharm Technol. 2014;5(2):148-54.
Pandey R, Sharma A, Singh S. A comprehensive review on extended-release pellets technology. Int J Pharm Sci Res. 2018;9(11):4451-60.
Patel NR, Patel NJ et al. A review on extended-release pellet-filled capsules. Int J Pharm Sci Res. 2017;8(11):4474-83.
Srinath MS, Prasanth VV. Extended-release pellet technology: a review. Int J Curr Pharm Res. 2017;9(3):1-5.
Heller J. Biodegrable polymers in controlled drug delivery. CRCCrit. Rev Thermdrug Carrier Syst. 1984;1:39-90.
Clarke G. Comparative gastrointestinal transit of pellet systems of varying density. International Journal of Pharmaceutics. 1995;114(1):1-11. doi: 10.1016/0378-5173(94)00200-O.
Jagdale SC, Chede SM, Gulwady R, Kuchekar BS, Lokhande PD, Shah TP, et al. Pulsatile multiparticulate drug delivery system for metoprolol succinate. Arch Pharm Res. 2011;34(3):369-76. doi: 10.1007/s12272-011-0303-0, PMID 21547667.
Gajdos B. Rotary granulators – Evaluation of process technology for pellet production using factorial design. Drugs made Ger. 1984;27:30-6.
Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int. J. Pharm. Tech. Prod Mfr. 1984;5:1-9.
Clarke GM, Newton JM, Short M. Comparative gastrointestinal transit of pellet systems of varying density. Int J Pharm. 1995;114:1-11.
Nastruzzi C, Cortesi R, Esposito E, Genovesi A, Spadoni A, Vecchio C, et al. Influence of formulation and process parameters on pellet production by powder layering technique. AAPS PharmSciTech. 2000;1:E9.
Ceballos A, Cirri M, Maestrelli F, Corti G, Mura P. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Farmaco. 2005;60(11-12):913-8. doi: 10.1016/j.farmac.2005.07.002.
Rashid HA, Heinämäki J, Antikainen O, Yliruusi J. Influence of the centrifugal granulating process on the properties of layered pellets. Eur J Pharm Biopharm. 2001;51(3):227-34. doi: 10.1016/s0939-6411(01)00129-1, PMID 11343887.
Botzolakis JE, Augsburger LL. Disintegrating agents in hard gelatin capsules. Part I: Mechanism of action. Drug Dev Ind Pharm. 1988;14(1):29-41. doi: 10.3109/03639048809151958.
Mandal U, Pal TK. Sustained release of metformin HCl from hydroxyl propyl methyl cellulose matrices: formulation and in vitro evaluation. Asian J Chem. 2008;20:1163-74.
Bodmeier R, Guo XD, Sarabia RE. The influence of buffer species and strength on DTZ HC1 release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D. Pharm Res. 1996;13:52-6.
Vertommen J, Rombaut P, Kinget R. Shape and surface smoothness of pellets made in a rotary processor. Int J Pharm. 1997;146(1):21-9. doi: 10.1016/S0378-5173(96)04754-0.
Kammili L, Senthil V, Varun R. Pelletization technology: A quick review. Int J Pharm Sci Res. 2011;2:1337-55.
Kiortsis S, Kachrimanis K, Broussali T, Malamataris S. Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component. Eur J Pharm Biopharm. 2005;59(1):73-83. doi: 10.1016/j.ejpb.2004.05.004, PMID 15567304.
Karmarkar AB, Gonjari ID, HN. Compatibility studies of diltiazem with commonly used excipients by DSC and FTIR. J Pharm Investig. 2013;43(2):137-45.
Patel S, Patel NJ, Shah R, Patel RB. Compatibility studies of diltiazem hydrochloride with pharmaceutical excipients by thermal and spectroscopic analysis. J Pharm Anal. 2016;6(2):81-9.
Kaushal AM, Semalty A, Semalty M, Kumar G. Formulation and evaluation of sustained release pellets of tramadol hydrochloride using different polymers. J Appl Pharm Sci. 2012;2(5):53-8.
Vithani K, Dharamsi A. Formulation and evaluation of extended-release pellets of diltiazem hydrochloride. J Appl Pharm Sci. 2017;7(10):214-20.
El-Dally M. Development and evaluation of controlled release diltiazem hydrochloride pellets coated with pH-independent polymethacrylates. AAPS PharmSciTech. 2014;15(4):1083-90.
Ibrahim MA, Ismail FA, Ismail RR, El-Sayed AM. Formulation and evaluation of controlled-release diltiazem hydrochloride matrix tablets. Drug Dev Ind Pharm. 2015;41(3):472-80.
Ragab MA, El-Helw AM, Ghorab MK, El-Gazayerly ON. Novel gastroretentive floating dosage form: development, optimization, and in vitro-in vivo evaluation. Drug Dev Ind Pharm. 2013;39(9):1391-402.
Gandhi R, Lal Kaul C, Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm Sci Technol Today. 1999;2(4):160-70. doi: 10.1016/S1461-5347(99)00136-4.
Lachman L, H, Liberman A, Kanig JL. Theory and practice of industrial pharmacy. Vol. 3. Mumbai: Varghese Publishing House; 1991. p. 296-302.
Vervaet C, Baert L, Remon JP. Extrusion-spheronisation a literature review. Int J Pharm. 1995;116(2):131-46. doi: 10.1016/0378-5173(94)00311-R.
Pavan Kumar G, Reddy P, P. Formulation and in vitro evaluation of extended-release pellets of diltiazem hydrochloride using the Wurster fluidized bed technique. J Pharm Res. 2012;5(1):349-54.
Thomas WYL, Joseph RR. Controlled release drug delivery systems. In: Gennaro AR. Remington: the science and practice of pharmacy. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 903-6.
DTZ hydrochloride extended-release Capsules monograph. 27th ed Rockville, Maryland, USA. United States Pharmacopoeia; 2004 :1953–55.
Ozturk AG, Ozturk SS, Palsson BO, Wheatley TA, Dressman JB. Mechanism of release from pellets coated with an ethyl cellulose-based film. J Control Release. 1990;14(3):203-13. doi: 10.1016/0168-3659(90)90160-U.
Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech. 2003;4(3):E31. doi: 10.1208/pt040331, PMID 14621963.
Hu LD, Liu Y, Tang X, Zhang Q. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur J Pharm Biopharm. 2006;64(2):185-92. doi: 10.1016/j.ejpb.2006.04.004.
Patel HirenP, Dr Patel JK, Patel RR, Dr Patel MP. International journal of pharma world research pellets: a general overview; 2010. p. 1-15.
Gondaliya D, Pundarikakshudu K. The fabrication and evaluation of the formulation variables of a controlled-porosity osmotic drug delivery system with DTZ hydrochloride. Pharm Technol. 2003;27:58-68.
Chaffman M, Brogden RN. DTZ: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387-454. doi: 10.2165/00003495-198529050-00001, PMID 3891302.
Shivanand P, Viral D, Manish G, Shailesh K. Formulation, characterization and in vitro evaluation of DTZ hydrochloride matrix tablets. Pharm Lett. 2010;2:482-8.
Abdelbary AA, El-Aziz AA, Mahmoud AA. Formulation and optimization of extended-release diltiazem HCl pellets using quality by design approach. El-say KM. AAPS PharmSciTech. 2012;13(3):1024-30.
Shirsat ND, Ghadge DM, Saudagar RB. Compatibility studies of diltiazem hydrochloride with different excipients using FTIR and DSC. Int J Pharm Res Dev. 2015;7(10):78-85.
Khedekar PB, Saudagar RB. Evaluation of compatibility of diltiazem hydrochloride with different pharmaceutical excipients by FTIR, DSC, and UV spectroscopy. World J Pharm Pharm Sci. 2018;7(10):664-75.
Fassihi A, Pousti I. Preparation and characterization of controlled-release diltiazem HCl microcapsules coated with pH-dependent polymethacrylates. Drug Dev Ind Pharm. 2008;34(10):1104-12.
Jelvehgari M, Barar J, Saeedi M. Optimization of formulation variables for the preparation of diltiazem HCl pellets using response surface methodology. Pharm Dev Technol. 2013;18(2):367-76.
Mohanachandran PS, Sindhumol PG, Sreelekha M, Rajeev C. Optimization and evaluation of extended-release diltiazem hydrochloride pellets prepared by the Wurster coating process. J Drug Deliv Sci Technol. 2014;24(2):117-25.
Dafale S, Vanarse V, Saudagar R. Formulation and evaluation of extended-release pellets of diltiazem hydrochloride by the Wurster fluidized bed technique. J Appl Pharm Sci. 2014;4(1):72-9.
Ashour HM, Ahmed OAA. Design and optimization of diltiazem hydrochloride extended-release pellets using Wurster fluidized bed coater. Drug Dev Ind Pharm. 2018;44(8):1327-36.
Amin AF, Khan ZI, Ali A. Development and optimization of controlled release pellets of diltiazem hydrochloride using response surface methodology. Drug Dev Ind Pharm. 2015;41(4):625-35.
Gondaliya D, Baria R, Shelat P. Design, optimization and evaluation of gastroretentive floating pellets of diltiazem hydrochloride. Int J Pharm Drug Anal. 2014;1(1):16-25.
Ibrahim MA, Ahmed TA, El-Badry M, El-Sayed AM. Formulation and optimization of diltiazem hydrochloride extended-release pellets using Box-Behnken design. AAPS PharmSciTech. 2016;17(2):349-35.
Davis SS, Khosia R, Wilson CG, Washington N. Gastrointestinal transit of a controlled release pellet formulation of tiaprofenic acid and the effect of food. Int J Pharm. 1987;35(3):253-8. doi: 10.1016/0378-5173(87)90137-2.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Sahil Arora, Charul Rathore
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
